Ontario Health
Cancer Care Ontario

Enrolment Form

CAR T-cell Therapy for Relapsed/Refractory Lymphoma (Second Line)

Note: This form should be completed and **funding approved** before apheresis is performed.

Completed form and supporting documentation should be submitted through the online portal: https://mft.cancercare.on.ca.
Username: CARTSubmission
Password: Contact our program at **OH-CCO_CARTSubmissions@ontariohealth.ca**

Ontario Health collects and uses information on this form in order to determine if the patient meets the eligibility and funding criteria for the CAR T-cell Therapy Program, resulting in reimbursement to the treating facility. They also collect and use information on this form for purposes of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system, including the delivery of services, pursuant to Section 45 of the Personal Health Information Protection Act, 2004.

As part of the evaluation of the request, it may be necessary for Ontario Health to disclose the patient's personal health information (PHI) to other administrative programs for health services and insured benefits at the Ministry of Health.

*Required Fields

1. Patient Profile

*Surname: _____

*Given Name: _____

*Date of Birth: DD-MMM-YYYY *(DD-MMM-YYYY or click arrow down button to use calendar to enter the date)*

*Gender: ◯ Male ◯ Female ◯ Other Height (cm): _____ Weight (kg): _____

*Province/Territory of Patient Residence: ◯ AB ◯ BC ◯ MB ◯ NB ◯ NL ◯ NT ◯ NS ◯ NU ◯ ON ◯ PE ◯ QC ◯ SK ◯ YT

*Postal Code of Patient Residence: _____

*Provincial/Territorial Health Card Number: _____

Note: If your patient is not a resident of Ontario, a funding approval letter from the patient's provincial/territorial Ministry of Health is required.

2. Enroling Site

*Enroling Site: _____

*Patient Chart Number (MRN) at Enroling Site: _____

*Enroling Physician: Given Name Surname

Enroling Physician CPSO Number (Ontario Only): _____

*Enroling Physician Specialty: _____

*Enroling Physician Email: _____

*Enroling Physician Cell Phone Number: XXX-XXX-XXXX

*Enroling Physician Fax Number: XXX-XXX-XXXX

Alternate Contact Email: _____

Note: If an alternate contact email is provided, the alternate contact will be copied on all email correspondence about this enrolment.

3. Treatment Centre and Product Information

Before submitting this form, confirm the CAR T-cell Therapy Centre has capacity and has agreed to treat your patient. Email or fax confirmation is required when submitting this enrolment package. CAR T-cell Therapy Centre contact details are available at https://www.cancercareontario.ca/en/find-cancer-services/car-t-cell-therapy-centres

*Will this patient receive CAR T-cell therapy in Ontario? ◯ Yes ◯ No

If patient will be treated **in Ontario**, select CAR T-cell therapy site:

- ◯ Juravinski Cancer Centre - Hamilton Health Sciences
- ◯ Kingston General Hospital - Kingston Health Sciences Centre
- ◯ Princess Margaret Cancer Centre - University Health Network
- ◯ The Ottawa Hospital

If patient will be treated **in another province** in Canada, please provide CAR T-cell therapy site name and city/province: _____

If patient will be treated **out of country**, please indicate the treating facility and **also complete section 8**:

- ◯ Roswell Park Comprehensive Cancer Center (Buffalo, New York)
- ◯ Cleveland Clinic (Cleveland, Ohio)
- ◯ Karmanos Cancer Institute (Detroit, Michigan)

*Treating Physician at CAR T-cell therapy site: Given Name Surname

*Requested CAR T-cell therapy product:

- ◯ Yescarta (axicabtagene ciloleucel)
- ◯ Breyanzi (lisocabtagene maraleucel)

Note: Switching CAR T-cell products will require replacement of the original funding letter that was issued. Contact the program immediately in case there is a need to use another product.

Anticipated date of apheresis : DD-MMM-YYYY *(DD-MMM-YYYY or click arrow down button to use calendar to enter the date)*

4. Funding Criteria

***A. The patient must meet the following criteria:** ☐ I confirm that my patient meets the funding criteria outlined below:

- Patient is 18 years old or older and has large B-cell lymphoma that is refractory[1] to first-line chemoimmunotherapy or that relapses[2] within 12 months following first-line chemoimmunotherapy
- Patient has received adequate standard first-line systemic therapy for aggressive lymphoma including an anti-CD20 monoclonal antibody (unless the tumor is determined to be CD20 negative) and an anthracycline or etoposide containing chemotherapy regimen (e.g., R-CHOP)[3,4]
- Patient is otherwise eligible for autologous stem cell transplant (ASCT)[5]
- Patient is sufficiently stable to facilitate planned CAR T-cell therapy (e.g., not rapidly progressing on temporizing therapy, no significant compromise of vital organ functions, no need for intubation or dialysis, does not require ICU/pressors and does not have active or uncontrolled infection) and has good performance status[6]
- Patient must have documented disease upon enrolment as indicated by an active FDG-PET scan or growth on CT scan and/or tissue biopsy (node or bone marrow)
- Patient has not previously received a non-cellular anti-CD19 therapy or CAR T-cell therapy

***B. Patient has the following diagnosis[7,8]:** Click arrow down to select a diagnosis (Do not write diagnosis on this field)

Notes: As evidence and clinical practice evolve, eligibility criteria is subject to change. Additional notes are provided on page 4.

1. Refractory disease - indicates progressive or partial or stable disease as the best response to the first-line standard therapy for aggressive lymphoma (e.g., R-CHOP). Treatment responses are as follows and further defined by the revised Lugano Response Criteria for Malignant Lymphoma (Cheson et al., 2014):
   a) Stable disease (SD) or progressive disease (PD) as best response to first-line therapy after at least 3 or more cycles of first-line therapy (e.g., 3 cycles of R-CHOP)
   b) Partial response (PR) as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ≤12 months following first-line therapy
2. Relapsed disease - indicates a complete remission/response (CR) to the first-line standard chemoimmunotherapy for aggressive lymphoma prior to a biopsy-proven relapse or recurrence ≤12 months following first-line therapy.
   a) Complete response (CR) - meets the complete metabolic response criteria as per PET scan-based response requirements or meets the complete radiological response criteria as per CT-scan based response requirements as defined in the revised Lugano Response Criteria for Malignant Lymphoma (Cheson et al., 2014).
3. Patients must not have completed more than one line of standard therapy for aggressive lymphoma. Patients who have received and completed multiple lines of therapy may be eligible for CAR T-cell therapy for the third-line or more indication.
4. Patients who are intolerant to the standard first-line therapy for agressive lymphoma are not currently eligible for funding. Patients who were started on standard second-line chemoimmunotherapy with the initial intent of proceeding with autologous stem cell transplant but are being switched to CAR T-cell therapy may be considered for funding.
5. Eligible means that the patient must be deemed fit for or able to tolerate ASCT.
6. Patients with primary CNS lymphoma and untreated secondary CNS lymphoma are currently not eligible for funding. Depending on how a patient was treated for active secondary CNS lymphoma, the patient may be eligible for second-line or third-line CAR T-cell therapy (e.g., patient treated upfront with R-CHOP and HD methotrexate as first-line may be considered for second-line CAR T-cell therapy).
7. Only diagnoses listed on section 4.B above may be eligible for funding.
8. Patients with Richter's transformation from chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are currently not eligible for funding.

5. Treatment History

Date Initiated	Date Completed	Name of Therapy/Regimen	No. of Cycles (if applicable)	Best Response to Therapy
MMMM, YYYY	MMMM, YYYY			Click arrow down to select
MMMM, YYYY	MMMM, YYYY			Click arrow down to select
MMMM, YYYY	MMMM, YYYY			Click arrow down to select
MMMM, YYYY	MMMM, YYYY			Click arrow down to select
MMMM, YYYY	MMMM, YYYY			Click arrow down to select
MMMM, YYYY	MMMM , YYYY			Click arrow down to select

6. Confirmation of Patient Suitability for Therapy

*A. CNS disease status:

- ◯ No CNS lymphoma
- ◯ Primary CNS lymphoma (not eligible for CAR T-cell therapy)
- ◯ Treated secondary CNS lymphoma - persistent disease (active)
- ◯ Treated secondary CNS lymphoma - in remission (inactive)

*B. Patient has acute life threatening bacterial, viral (HIV, active hepatitis B or C) or fungal infection:

- ◯ No Infection
- ◯ Controlled Infection
- ◯ Uncontrolled Infection

*C. Karnofsky Performance Status (KPS) ≤70%: ◯ Yes ◯ No

Date of KPS assessment: DD-MMM-YYYY *(DD-MMM-YYYY or click arrow down button to use calendar to enter the date)*

Renal Function:

*D. Creatinine ≥141.44 µmol/L (1.6 mg/dL): ◯ Yes ◯ No

*E. Estimated glomerular filtration rate (eGFR) ≤45 ml/min/1.73m^2: ◯ Yes ◯ No

Liver Function:

*F. ALT or AST ≥3x upper limit of normal value: ◯ Yes ◯ No

*G. Bilirubin ≥2x upper limit of normal value: ◯ Yes ◯ No

Pulmonary Function:

*H. Pulse oxygenation ≤91% on room air: ◯ Yes ◯ No

Cardiac Function:

*I. Left ventricular ejection fraction (LVEF) ≤40% confirmed by echocardiogram or multiple-gated acquisition (MUGA) scan or radionuclide angiography: ◯ Yes ◯ No

Bone Marrow Function:

*J. Absolute neutrophil count (ANC) ≤1.0x10^9/L: ◯ Yes ◯ No

*K. Absolute lymphocyte count (ALC) <0.1x10^9/L: ◯ Yes ◯ No

Note: If ALC is below 0.1x10^9/L, application can be considered; but for apheresis to proceed, ALC must be at least 0.1x10^9/L.

*L. Hemoglobin ≤80 g/L (8.0 g/dL) and/or transfusion dependent: ◯ Yes ◯ No

*M. Platelets ≤50x10^9/L: ◯ Yes ◯ No

7. Additional Notes

a. Treatment with axicabtagene ciloleucel or lisocabtagene maraleucel is a one-time therapy.
b. Axicabtagene ciloleucel or lisocabtagene maraleucel should not be used in combination with other treatments for relapsed/refractory lymphoma.
c. Patients who have transformed DLBCL from follicular or other indolent lymphoma and have received an anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20 negative), and an anthracycline or etoposide-containing chemotherapy regimen (e.g., R-CHOP) based only on high clinical suspicion or prior to a repeat biopsy documenting transformation may be considered for funding.
d. A patient with another malignancy may be considered for CAR T-cell therapy if they meet the funding criteria, are suitable for therapy, and are either in complete remission or not undergoing any active drug therapy that could cause serious toxicity and preclude them from receiving CAR T-cell therapy.
e. For CNS lymphomas, active or persistent CNS disease is defined as recent neurologic sign/symptoms, and/or positive imaging studies (MRI, PET scan) and/or positive cerebrospinal fluid (CSF) study.
f. Patients with an active, uncontrolled infection should not start treatment with CAR T-cell therapy until the infection has resolved or has been appropriately treated. This includes both the lymphodepleting chemotherapy and the CAR T-cell infusion.
g. Patients must meet the funding criteria at the time of enrolment and must continue to be eligible and suitable for therapy at the time of product infusion.

8. Out-of-Country Applications - Additional Requirements

Only complete this section if you are an Ontario physician applying for an Ontario patient to be treated out-of-country:

1. Submit all the documents listed under "Supporting Documents" in section 10.
2. Download, complete and submit the Ministry form “Request for Prior Approval for Full Payment of Insured Out-of-Country (OOC) Health Services." The form can be found in the Central Forms Repository at: https://forms.mgcs.gov.on.ca/en/dataset/on00314

Complete as indicated below:

- Part 1: Patient name, OHIN number, date of birth, mailing address and telephone number
- Part 2: Physician name, office address, telephone number, email address, and OHIP billing number
- Part 3: All required fields, check box confirming completion of CCO Questionnaire; in lieu of the questionnaire form, a completed copy of this enrolment form will be submitted
- Part 4: Auto-completed
- Part 5: All required fields
- Part 6: Submit a completed copy of this enrolment form

9. Acknowledgement

☐ *Yes, I confirm that the patient named above, or relevant substitute decision-maker where applicable, consents that Ontario Health collects and uses information on this form to make funding decisions pursuant to section 38(1)(b) of the Personal Health Information Protection Act, 2004; and for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system, including the delivery of services, pursuant to section 45 of the Personal Health Information Protection Act, 2004. As part of the evaluation and reimbursement process for the CAR T-cell Therapy Program, it may be necessary for Ontario Health to disclose or share the patient's personal health information to other administrative programs for health services and insured benefits at the Ministry of Health or at Ontario Health.

10. Supporting Documents

If the enrolment is for an Out-of-Country treatment for an Ontario patient, the following documentation (from **Lists A and B**) **must be** submitted with the enrolment form. The Ministry form "Request for Prior Approval for Full Payment of Insured Out-of-Country (OOC) Health Services" must also be included in the enrolment package.

If the enrolment is for in-Ontario treatment, the documents under **List A must be** submitted and documents under **List B** should be available upon request (including for the purpose of audit) to confirm eligibility.

***List A: Required upon enrolment**

- ☐ If any of the answers to section 6 are "Yes", submit relevant and recent laboratory results showing adequate organ function (e.g., kidney and liver function tests, viral serology, cardiac ECHO/MUGA)
- ☐ Pathology report
- ☐ Recent clinic notes that describe the patient's current clinical status and rationale for CAR T-cell therapy over other treatment options. Include any specialist notes (e.g., BMT, neurology, nephrology, cardiology) that informed the treatment plan
- ☐ Bone Marrow (BM) studies including most recent studies
- ☐ Pre- and post-treatment imaging reports e.g., CT scan (post-treatment imaging reports must be within the last 30 days)
- ☐ If the request is from a treating physician outside an Ontario CAR T-cell treating facility, email or fax from the treating facility/physician confirming that they have capacity and are willing to accept this patient
- ☐ If the request is for treatment out of country, email or fax from the Ontario CAR T-cell treating facilities confirming no capacity and email or fax from the out of country treating facility confirming their capacity and willingness to accept this patient
- ☐ If the request is for a non-Ontario resident, a funding approval letter from the patient's provincial/territorial Ministry of Health is required, specifying CAR T-cell product(s) that is/are funded by the patient's provincial/territorial Ministry of Health

List B: Available upon request

- ☐ Cerebrospinal Fluid (CSF) studies documenting CNS disease status (within the last 30 days)
- ☐ Documentation of CD19 tumour expression in BM or peripheral blood by flow cytometry (if done)
- ☐ Multidisciplinary cancer conference (MCC)/tumour board notes (if available)

*By checking this box, I certify that the information set out in this questionnaire is true and accurate, to the best of my knowledge: ☐ Yes

*Enroling Physician: Given Name Surname *Date: DD-MMM-YYYY *(DD-MMM-YYYY or click arrow down button to use calendar to enter the date)*

Need this information in an accessible format? 1-877-280-8538, TTY 1-800-855-0511, info@ontariohealth.ca